‘Jumping Genes’ Support Immune Cells in Tissue Researchers at the Leibniz Institute for Immunotherapy (LIT) describe a new type of regulation of immune cells by so-called 'jumping genes.' Read more: https://lnkd.in/dPa935XG For more information, please visit the full article in the journal "Immunity": Malte Simon, Philipp Stüve, Lisa Schmidleithner, Sebastian Bittner, Niklas Beumer, Nicholas Strieder, Christian Schmidl, Asmita Pant, Claudia Gebhard, Andreas Eigenberger, Michael Rehli, Lukas Prantl, Thomas Hehlgans, Benedikt Brors, Charles D Imbusch, Michael Delacher, and Markus Feuerer. Single cell chromatin accessibility and transposable element landscapes reveal shared features of tissue-residing immune cells. Immunity, 2024. https://lnkd.in/dH--_hfT #immunology #immunotherapy #immunity
LIT - Leibniz Institute for Immunotherapy
Forschung
Regensburg, Bavaria 698 Follower:innen
Cells built to cure
Info
The Leibniz Institute for Immunotherapy (LIT) is an institute within the Leibniz Association located in Regensburg, Germany. Our mission is to develop innovative therapies for the treatment of cancer, autoimmunity, and chronic inflammation. By reprogramming immune cells through synthetic and pharmacological strategies, we build cells that save lives.
- Website
-
https://lit.eu
Externer Link zu LIT - Leibniz Institute for Immunotherapy
- Branche
- Forschung
- Größe
- 51–200 Beschäftigte
- Hauptsitz
- Regensburg, Bavaria
- Art
- Bildungseinrichtung
- Gegründet
- 2010
Orte
-
Primär
Wegbeschreibung
Franz-Josef-Strauß-Allee 11
Regensburg, Bavaria 93053 , DE
Beschäftigte von LIT - Leibniz Institute for Immunotherapy
Updates
-
Leibniz Institute for Immunotherapy (LIT) receives Total E-Quality award for equal opportunity strategy Due to exemplary actions in the field of equal opportunity-oriented personnel and organizational policies, Leibniz Institute for Immunotherapy is awarded the TOTAL E-QUALITY Deutschland e. V. award for the second time, which is valid for the years 2024 to 2026. https://lnkd.in/gTJG_TMq #totalequality #equalopportunity #immunotherapy
Leibniz Institute for Immunotherapy (LIT) receives Total E-Quality award for equal opportunity strategy
https://lit.eu
-
International LIT Symposium “Synthetic Immunology / Synthetic Biology” in Regensburg: More than 150 leading scientists from around the world discussed latest developments in immunological research and the treatment of diseases such as cancer, autoimmune diseases, and chronic inflammation at the International Symposium of the Leibniz Institute for Immunotherapy June 26th – 27th, 2024 in Regensburg. Read more: https://lnkd.in/dxQv4fnf Speakers: Hinrich Abken, Franziska Blaeschke, Markus Feuerer, Luca Gattinoni, Alena Gros Vidal, John Haanen, michael jensen, md, Markus Jeschek, Carl June, Christopher A. Klebanoff, M.D., Megan Levings, John Maher, Marcela Maus Jens Meiler, Cristina Puig Saus, Shimon Sakaguchi, Kilian Schober, Velia Siciliano, Naomi Taylor, Fabian Theis #immunology #immunotherapy #syntheticimmunology #syntheticbiology
-
-
-
-
-
2
-
-
CAR T-REX Consortium brings together experts in Cell and Gene therapies for General Assembly at CiQUS, Universidade de Santiago de Compostela (Spain)
📢 Press Release Available Partners from CAR T-REX recently met at CiQUS - Center for Research in Biological Chemistry and Molecular Materials, Universidade de Santiago de Compostela, Spain, for the first in-person meeting. The CAR T-REX consortium brings together a multidisciplinary group of internationally recognised experts and companies across Europe and Israel. The project started in June 2023 and runs for 4 years. CAR T-REX aims to build novel auto-regulated genetic circuits controlled by microRNAs in immune cells, employ a novel high-performance non-viral gene delivery platform (TraffikGene®), select and benchmark the best-performing circuits in preclinical settings, as well as execute GMP-like manufacturing runs for the final CAR T-cell product. Overall, the CAR T-REX consortium expects to lay the foundation of an improved technology with potential for significant scientific and societal impact. Marisa Juanes from CiQUS highlights: "Welcoming the CAR T-REX consortium to CiQUS was a remarkable experience. The assembly not only highlighted the collaborative spirit among our distinguished members but also set the stage for groundbreaking advancements in CAR T-cell therapies." Rui A. Sousa, CEO of Stemmatters & Coordinator, adds: “The General Assembly of the CAR T-REX project facilitated important scientific discussions to maximise the impact of the consortium to tackle the treatment of solid tumours. During the next phase of the project, we will be working together to integrate the partners’ technology and expertise into the development of a novel CAR T-cell therapy.” Check out the full press release on the CAR T-REX project’s website 👇 https://lnkd.in/d9_5nqJm #pressrelease #partners #collaboration #cartrex #innovation #cartcell #celltherapy #solidtumours #cancer #CGT #pathfinderopen #EIC #horizoneurope
-
-
Bringing research results of gene and cell therapy to the clinic faster: Leibniz scientists significantly involved in national strategy for gene and cell-based therapies. https://lnkd.in/dWG7AaYe #immunotherapy
Bringing research results of gene and cell therapy to the clinic faster
https://lit.eu
-
LIT - Leibniz Institute for Immunotherapy hat dies direkt geteilt
📢 📢 📢 Call for abstracts! 📢 📢 📢 Come to Regensburg and present your work! We welcome abstracts for the poster session and lightning talks of the International LIT Symposium on Wednesday, June 26th 2024! The best abstracts will be invited as posters and / or lightning talks. Register here and submit your abstract: https://lit-symposium.org/ Speakers: Hinrich Abken, Franziska Blaeschke, Markus Feuerer, Luca Gattinoni, Alena Gros Vidal, John Haanen, michael jensen, md, Markus Jeschek, Carl June, Christopher A. Klebanoff, M.D., Megan Levings, John Maher, Jens Meiler, Cristina Puig Saus, Shimon Sakaguchi, Christian Schmidl, Kilian Schober, Velia Siciliano, Naomi Taylor, Fabian Theis
-
Luca Gattinoni and Matthias Edinger from the Leibniz Institute for Immunotherapy (LIT) and University Hospital Regensburg (UKR) have received a 2.6 million euro grant from the German Cancer Aid. The funding will support an innovative clinical study using stem-like CAR T cells to treat patients with advanced lymphomas. Read more: https://lnkd.in/d25mt_-w #immunotherapy #immunology
€2.6 Million Funding Boosts Ground-breaking CAR T Cell Therapy Study in Advanced Lymphomas
https://lit.eu
-
The Pint of Science festival is starting soon! A group of young LIT scientists are the organizers of this year's Regensburg Pint of Science event. Come listen to inspiring scientific talks, while sipping a pint of beer together! We are looking forward to see you there! - Join us on three evenings in Regensburg - More infos and tickets: https://lnkd.in/ddu44_Kx
-
📢 📢 📢 Call for abstracts! 📢 📢 📢 Come to Regensburg and present your work! We welcome abstracts for the poster session and lightning talks of the International LIT Symposium on Wednesday, June 26th 2024! The best abstracts will be invited as posters and / or lightning talks. Register here and submit your abstract: https://lit-symposium.org/ Speakers: Hinrich Abken, Franziska Blaeschke, Markus Feuerer, Luca Gattinoni, Alena Gros Vidal, John Haanen, michael jensen, md, Markus Jeschek, Carl June, Christopher A. Klebanoff, M.D., Megan Levings, John Maher, Jens Meiler, Cristina Puig Saus, Shimon Sakaguchi, Christian Schmidl, Kilian Schober, Velia Siciliano, Naomi Taylor, Fabian Theis
-
🚨 🚨 🚨 Job - Alert #scientist ! LIT - Leibniz Institute for Immunotherapy is looking for: ➡ Computational Scientist / Bioinformatician (m/f/d) Apply before: 2024-05-05 Read more here: https://lnkd.in/dP_EcDAm #jobs #hiring #research #engineering #computerscience #informatics #bioinformatics #bioinformatician #data #computationalbiology #biostatistics Universität Regensburg
Computational Scientist / Bioinformatician (m/f/d)
academiceurope.com